CEL SCI CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CEL SCI CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Sep 30, 2014 | $67.8K | Dec 23, 2014 |
| FY2014 | Jun 30, 2014 | $15.9K | Dec 23, 2014 |
| FY2014 | Mar 31, 2014 | $67.2K | Dec 23, 2014 |
| FY2014 | Dec 31, 2013 | $113.1K | Dec 23, 2014 |
| FY2014 | Sep 30, 2013 | $15.5K | Dec 23, 2014 |
| FY2014 | Jun 30, 2013 | $113.7K | Dec 23, 2014 |
| FY2014 | Mar 31, 2013 | $15.4K | Dec 23, 2014 |
| FY2014 | Dec 31, 2012 | $15.0K | Dec 23, 2014 |
| FY2013 | Sep 30, 2012 | $108.0K | Dec 27, 2013 |
| FY2013 | Jun 30, 2012 | $35.0K | Dec 27, 2013 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($25.41M) | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | ($26.92M) | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | ($32.37M) | Jan 13, 2025 |
| FY2023 | Sep 30, 2022 | ($36.70M) | Dec 21, 2023 |
| FY2022 | Sep 30, 2021 | ($36.36M) | Dec 27, 2022 |
| FY2021 | Sep 30, 2020 | ($30.26M) | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | ($22.13M) | Dec 29, 2020 |
| FY2019 | Sep 30, 2018 | ($31.84M) | Dec 23, 2019 |
| FY2018 | Sep 30, 2017 | ($14.36M) | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | ($11.51M) | Dec 29, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($24.81M) | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | ($26.35M) | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | ($31.48M) | Jan 13, 2025 |
| FY2023 | Sep 30, 2022 | ($36.06M) | Dec 21, 2023 |
| FY2022 | Sep 30, 2021 | ($36.19M) | Dec 27, 2022 |
| FY2021 | Sep 30, 2020 | ($28.99M) | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | ($20.20M) | Dec 29, 2020 |
| FY2019 | Sep 30, 2018 | ($16.77M) | Dec 23, 2019 |
| FY2018 | Sep 30, 2017 | ($21.41M) | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | ($23.65M) | Dec 29, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $15.89M | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | $18.16M | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | $22.47M | Jan 13, 2025 |
| FY2023 | Sep 30, 2022 | $25.36M | Dec 21, 2023 |
| FY2022 | Sep 30, 2021 | $23.11M | Dec 27, 2022 |
| FY2021 | Sep 30, 2020 | $17.84M | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | $12.66M | Dec 29, 2020 |
| FY2019 | Sep 30, 2018 | $10.91M | Dec 23, 2019 |
| FY2018 | Sep 30, 2017 | $15.61M | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | $17.45M | Dec 29, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($17.12M) | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | ($18.81M) | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | ($22.85M) | Jan 13, 2025 |
| FY2023 | Sep 30, 2022 | ($18.24M) | Dec 21, 2023 |
| FY2022 | Sep 30, 2021 | ($18.79M) | Dec 27, 2022 |
| FY2021 | Sep 30, 2020 | ($15.28M) | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | ($16.32M) | Dec 29, 2020 |
| FY2019 | Sep 30, 2018 | ($13.39M) | Dec 23, 2019 |
| FY2018 | Sep 30, 2017 | ($13.79M) | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | ($23.08M) | Dec 29, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $38.1K | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | $94.9K | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | $361.9K | Jan 13, 2025 |
| FY2023 | Sep 30, 2022 | $637.9K | Dec 21, 2023 |
| FY2022 | Sep 30, 2021 | $9.02M | Dec 27, 2022 |
| FY2021 | Sep 30, 2020 | $2.65M | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | ($177.8K) | Dec 29, 2020 |
| FY2019 | Sep 30, 2018 | $1.0K | Dec 23, 2019 |
| FY2018 | Sep 30, 2017 | $10.5K | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | $31.4K | Dec 29, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $28.16M | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | $26.99M | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | $30.53M | Jan 13, 2025 |
| FY2023 | Sep 30, 2022 | $50.52M | Dec 21, 2023 |
| FY2022 | Sep 30, 2021 | $75.87M | Dec 27, 2022 |
| FY2021 | Sep 30, 2020 | $40.54M | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | $27.62M | Dec 29, 2020 |
| FY2019 | Sep 30, 2018 | $29.59M | Dec 23, 2019 |
| FY2018 | Sep 30, 2017 | $22.92M | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | $24.89M | Dec 29, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $12.20M | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | $14.12M | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | $17.31M | Jan 13, 2025 |
| FY2023 | Sep 30, 2022 | $18.36M | Dec 21, 2023 |
| FY2022 | Sep 30, 2021 | $19.34M | Dec 27, 2022 |
| FY2021 | Sep 30, 2020 | $20.81M | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | $22.49M | Dec 29, 2020 |
| FY2019 | Sep 30, 2018 | $29.59M | Dec 23, 2019 |
| FY2018 | Sep 30, 2017 | $26.26M | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | $25.57M | Dec 29, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $15.96M | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | $12.87M | Dec 29, 2025 |
| FY2025 | Sep 30, 2023 | $13.21M | Dec 29, 2025 |
| FY2024 | Sep 30, 2022 | $32.16M | Jan 13, 2025 |
| FY2023 | Sep 30, 2021 | $56.53M | Dec 21, 2023 |
| FY2022 | Sep 30, 2020 | $19.73M | Dec 27, 2022 |
| FY2021 | Sep 30, 2019 | $5.13M | Dec 21, 2021 |
| FY2020 | Sep 30, 2018 | $916 | Dec 29, 2020 |
| FY2019 | Sep 30, 2017 | ($3.34M) | Dec 23, 2019 |
| FY2018 | Sep 30, 2016 | ($679.2K) | Dec 19, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($539.42M) | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | ($514.01M) | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | ($487.09M) | Jan 13, 2025 |
| FY2023 | Sep 30, 2022 | ($454.90M) | Dec 21, 2023 |
| FY2022 | Sep 30, 2021 | ($418.20M) | Dec 27, 2022 |
| FY2021 | Sep 30, 2020 | ($381.84M) | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | ($353.73M) | Dec 29, 2020 |
| FY2019 | Sep 30, 2018 | ($331.59M) | Dec 23, 2019 |
| FY2018 | Sep 30, 2017 | ($299.75M) | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | ($285.39M) | Dec 29, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | $22.67M | Dec 27, 2022 |
| FY2022 | Sep 30, 2021 | $36.06M | Dec 27, 2022 |
| FY2021 | Sep 30, 2020 | $15.51M | Dec 21, 2021 |
| FY2021 | Sep 30, 2019 | $8.44M | Dec 21, 2021 |
| FY2020 | Sep 30, 2018 | $10.31M | Dec 29, 2020 |
| FY2019 | Sep 30, 2017 | $2.37M | Dec 23, 2019 |
| FY2018 | Sep 30, 2016 | $2.92M | Dec 19, 2018 |
| FY2017 | Sep 30, 2015 | $5.73M | Dec 29, 2017 |
| FY2016 | Sep 30, 2014 | $8.51M | Dec 11, 2017 |
| FY2016 | Sep 30, 2013 | $41.6K | Dec 11, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | 0 | Dec 27, 2022 |
| FY2022 | Sep 30, 2021 | 0 | Dec 27, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Dec 21, 2021 |
| FY2019 | Sep 30, 2019 | 0 | Dec 23, 2019 |
| FY2019 | Sep 30, 2018 | (1) | Dec 23, 2019 |
| FY2018 | Sep 30, 2017 | (1) | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | (2) | Dec 29, 2017 |
| FY2016 | Sep 30, 2015 | (2) | Dec 11, 2017 |
| FY2016 | Jun 30, 2015 | (1) | Dec 11, 2017 |
| FY2016 | Mar 31, 2015 | (4) | Dec 11, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (6) | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | (15) | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Jan 13, 2025 |
| FY2022 | Sep 30, 2022 | 0 | Dec 27, 2022 |
| FY2022 | Sep 30, 2021 | 0 | Dec 27, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Dec 21, 2021 |
| FY2019 | Sep 30, 2019 | 0 | Dec 23, 2019 |
| FY2019 | Sep 30, 2018 | (1) | Dec 23, 2019 |
| FY2018 | Sep 30, 2017 | (1) | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | (2) | Dec 29, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 8.02M | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | 2.13M | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | 47.42M | Jan 13, 2025 |
| FY2023 | Sep 30, 2022 | 43.45M | Dec 21, 2023 |
| FY2022 | Sep 30, 2021 | 43.21M | Dec 27, 2022 |
| FY2021 | Sep 30, 2020 | 38.73M | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | 35.23M | Dec 29, 2020 |
| FY2019 | Sep 30, 2018 | 28.03M | Dec 23, 2019 |
| FY2018 | Sep 30, 2017 | 11.90M | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | 6.25M | Dec 29, 2017 |